Csat+® (Pharmactive Carob Extract)
Csat+® is Pharmactive Biotech Products' branded carob (Ceratonia siliqua) extract for weight management, a NutraIngredients Awards 2020 finalist for Weight Management Ingredient of the Year. It is standardized to at least 25.1% Sliminoids®, Pharmactive's term for the combined carob bioactives it assays: galactomannan at least 20%, inositols at least 5% (mainly D-pinitol) and gallic acid at least 0.1%. Pharmactive proposes three mechanisms: fiber-driven satiety, inositol-linked insulin signalling and polyphenol antioxidant activity. The supporting work is laboratory and mouse research. No clinical trial of Csat+ itself has been published. International patent (WO 2019/068466 A1). Despite the similar-sounding name, Csat+ is carob-based, not saffron-based; Pharmactive's saffron ingredient is Affron®.
Benefits
Galactomannan fiber: the proposed satiety mechanism
Galactomannan is a viscous soluble fiber, and fiber is proposed to promote fullness, but the human carob studies cited here used gram amounts. Studies giving 5 to 50 g of carob pulp fiber measured ghrelin, glucose and blood fats, not appetite, and a carob snack eaten before a meal reduced hunger. Csat+ is about 20% galactomannan, so a capsule supplies far less. No study has measured appetite in people taking Csat+.
Inositols: a small amount of a studied compound
Csat+ is specified to at least 5% inositols, and Pharmactive's published breakdown is mostly D-pinitol (about 4.7%) with only about 0.35% myo-inositol. A 90-day trial in adults with prediabetes did lower HbA1c and fasting glucose, but it used another company's inositol-standardized carob concentrate at 6.66 g a day, about 1.1 g of inositols, which would take roughly 22 g of Csat+ to match.
α-Amylase inhibition: a laboratory finding
Carob water decoctions inhibit α-amylase and α-glucosidase in test-tube assays, although the strongest inhibition came from leaf and stem-bark preparations rather than the pod material used in supplements. One human study pointed the other way: adding 5 g or 10 g of carob pulp fiber to a 50 g glucose drink raised plasma glucose by 47% and 64% and insulin by about 20-25% versus the glucose drink alone.
Blood lipids: carob fiber trials, not Csat+
Reviews of carob describe lipid lowering by its polyphenols and insoluble fiber through the gut, liver and fat tissue. In two placebo-controlled trials in adults with high cholesterol, carob pulp fiber (15 g a day in foods, or 8 g a day of a polyphenol-rich fiber) lowered LDL cholesterol by about 10% and, from baseline, 22%. Carob syrup and carob concentrate trials found no lipid difference from control groups. Csat+ is untested in people.
Prebiotic fermentation: test-tube evidence
Csat+ is specified to at least 2% oligofructoses, and when it was incubated with human faecal bacteria in an anaerobic laboratory model it shifted microbial composition and raised short-chain fatty acid output compared with a control medium. That work was done in glassware. It did not measure appetite, body weight or any outcome in a person, and no study has shown a microbiome change in people taking Csat+.
Antioxidant activity: animal and laboratory data
Gallic acid is the main phenolic measured in carob pod, and Csat+ is specified to at least 0.1%. In mice fed a high-fat, high-sugar diet, Csat+ raised the expression of antioxidant enzymes and lowered inflammatory markers such as IL-6, TNFα and MCP-1 in liver, muscle, fat and aortic tissue. Those were animal experiments funded by the manufacturer, and oxidative stress markers have not been measured in people taking Csat+.
Standardisation and identity
Csat+ is made to a published specification, with galactomannan, inositols, gallic acid and oligofructoses each assayed, so batches should be more consistent than unstandardised carob powder. The extraction process is covered by patent WO 2019/068466 A1, co-assigned to Pharmactive, the Spanish research council CSIC and the Universidad Autónoma de Madrid. A specification and a patent describe how an ingredient is made, not whether it works.
Mechanism of action
Viscous fiber gastric distension
Galactomannan from carob seed is a viscous soluble fiber. Viscous fibers are proposed to add bulk in the stomach and slow its emptying, which could promote fullness. The carob studies cited here gave grams of fiber, and a capsule of a 20% galactomannan extract carries far less; no study has measured this effect with Csat+.
IPG second-messenger insulin signaling
Inositols such as D-pinitol are proposed to act through inositol phosphoglycan (IPG) messengers involved in insulin signalling. Csat+ supplies mostly D-pinitol, in small amounts, and this pathway has not been measured in people taking Csat+.
α-Amylase enzymatic inhibition
In test-tube assays, carob water decoctions (most strongly from leaf and stem bark) inhibited α-amylase and α-glucosidase, the enzymes that break starch and sugars into absorbable glucose. Slowing them could blunt the rise in blood glucose after a meal, but this has not been shown in the human gut after a dose of Csat+.
Gut, liver and fat-tissue lipid effects
Reviews of carob describe lipid lowering by its polyphenols and insoluble fiber through effects on the gut, liver and fat tissue. The carob fiber trials that lowered LDL cholesterol used 8 to 15 g a day, and no lipid effect has been tested at Csat+ doses.
Clinical trials
Animal experiment, not a human trial. C57BL/6J mice were fed a high-fat, high-sugar diet for 26 weeks with or without Csat+ at 4.8% of the diet by weight. Run by Universidad Autónoma de Madrid physiologists and funded by Pharmactive, which sells the ingredient. (de la Fuente-Fernández et al. 2020, Antioxidants (Basel))
Male C57BL/6J mice with diet-induced metabolic syndrome. No humans were studied.
Csat+ lowered blood glucose, HOMA-IR, insulin, total and LDL cholesterol and IL-6 in the mice, prevented diet-induced hypertension and improved vascular function. Appetite was not measured directly, and results in mice eating the extract at 4.8% of their diet do not show what a capsule does in a person.
Animal experiment, not a human trial. Mice with diet-induced metabolic syndrome had two weeks of calorie reduction, with or without aerobic training, with or without Csat+ at 4.8% of the diet. Carried out with and funded by the manufacturer. (de la Fuente-Fernández et al. 2022, Antioxidants (Basel))
Male C57BL/6J mice with diet-induced metabolic syndrome. No humans were studied.
Csat+ added to calorie restriction produced more body-weight loss and less epididymal fat than calorie restriction or exercise alone, and improved insulin sensitivity in liver and skeletal muscle. Appetite was not measured directly, and these mouse results do not establish effects in people.
A 90-day randomized, double-blind, placebo-controlled trial (registered NCT07379931) of a carob liquid concentrate standardized to inositols (15.5% D-pinitol, 165.2 mg/g total inositols), taken as 6.66 g/day in two sachets before lunch and dinner. It was manufactured and funded by Planttech Biotechnology Spain S.L., a different company, and is not standardized to galactomannan, so it is not a trial of Csat+. (Pérez-Piñero et al. 2026, Nutrients)
52 adults with confirmed prediabetes (25 active, 27 placebo), 27 men and 25 women, mean age 45.6 years, mean BMI about 28.
Against placebo, the carob concentrate lowered HbA1c (−0.29% versus −0.04%, p<0.001), fasting glucose, the glucose area under the curve during an oral glucose tolerance test (p=0.015), the insulin area under the curve (p=0.019) and the glucose peak (p=0.034), and improved HOMA-IR (p=0.038) and QUICKI (p=0.024). Fasting insulin fell within the active group but the difference from placebo was not significant (p=0.071). Body weight, BMI and fat mass did not change in either group, and neither did total cholesterol or HDL; LDL differed between groups (p=0.003) because it rose in the placebo group rather than falling on the active product. The product was well tolerated over 90 days with no adverse effects recorded.
Side effects and drug interactions
Common Potential side effects
Important Drug interactions
Frequently asked questions about Csat+® (Pharmactive Carob Extract)
What is Csat+?
Csat+® is Pharmactive Biotech Products' branded carob (Ceratonia siliqua) extract for weight management, a NutraIngredients Awards 2020 finalist for Weight Management Ingredient of the Year. It is standardized to at least 25.
What is Csat+ used for?
Csat+ is researched primarily for Metabolic Health. Galactomannan is a viscous soluble fiber, and fiber is proposed to promote fullness, but the human carob studies cited here used gram amounts.
What is the recommended dosage of Csat+?
No dose of Csat+ has been tested in people. No finished-product serving size is published; the two mouse studies fed the extract at 4.8% of total diet by weight, which gives no capsule dose. Always follow the product label and check with a healthcare provider for personal advice.
Is Csat+ safe, and does it have side effects?
Side effects and cautions reported for Csat+ include: Carob is a long-used food, eaten as a chocolate substitute and natural sweetener, but Csat+ is more concentrated than dietary carob and its long-term safety as a supplement has not been studied. It may also interact with some medications. Csat+ is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.
Does Csat+ interact with any medications?
Possible interactions include: Diabetes medications: a carob concentrate lowered fasting glucose and HbA1c in adults with prediabetes, so effects could add up; monitor blood glucose. No interaction studies exist for Csat+. If you take prescription medication, check with a pharmacist or doctor before using it.
How strong is the scientific evidence for Csat+?
NutraSmarts rates the evidence for Csat+ as Preliminary (1 out of 5). It is backed by 3 study summaries and 14 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.
References(14 citations)
Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.
- Effects of Specific Carob (Ceratonia siliqua L.) Liquid Concentrate on Glucose Metabolism in Subjects with Prediabetes: A Randomized Double-Blind Controlled Clinical Trial. Nutrients. 2026;18(10):1521. doi: 10.3390/nu18101521.PubMedUsed to support: 90-day randomized, double-blind, placebo-controlled trial in 52 adults with prediabetes (25 active, 27 placebo) using a carob liquid concentrate standardized to inositols (15.5% D-pinitol; 165.2 mg/g total inositols) at 6.66 g/day, taken as two sachets 30 minutes before lunch and dinner. Compared with placebo, HbA1c fell 0.29% versus 0.04% (p<0.001), with lower fasting glucose (p<0.001), lower glucose area under the curve during an oral glucose tolerance test (p=0.015), lower insulin area under the curve (p=0.019), a lower glucose peak (p=0.034) and improved HOMA-IR (p=0.038) and QUICKI (p=0.024). Fasting insulin fell within the active group but did not differ significantly from placebo (p=0.071). Body weight, BMI and fat mass were unchanged, as were total cholesterol and HDL; the between-group difference in LDL (p=0.003) reflected a rise in the placebo group rather than a fall on the active product. The tested product was manufactured and funded by Planttech Biotechnology Spain S.L. and is a different carob preparation from Csat+.
- Increased acylated plasma ghrelin, but improved lipid profiles 24-h after consumption of carob pulp preparation rich in dietary fibre and polyphenols. Br J Nutr. 2007;98(6):1170-7. doi: 10.1017/S0007114507777127.PubMedUsed to support: Randomized controlled crossover study in 19 healthy volunteers eating foods containing 50 g of carob pulp fiber. On the following day, post-meal triglyceride (p=0.033) and free fatty acid (p<0.001) responses were lower than control, but fasting acylated ghrelin, the form of the hormone that drives hunger, was higher (p=0.046), and the post-meal glucose response was also higher (p=0.029). Fasting glucose, triglycerides, total ghrelin, insulin and leptin were unchanged. Appetite was not measured, and cholesterol was not measured at all.
- Lipid-Lowering Effects of Carob Extracts (Ceratonia siliqua): Proposed Mechanisms and Clinical Importance. Front Pharmacol. 2022;13:921123. doi: 10.3389/fphar.2022.921123.PubMedUsed to support: Narrative review describing how carob pulp, through its polyphenols and insoluble fiber, may lower blood lipids through effects on the gastrointestinal tract, liver and adipose tissue. It summarises existing human and animal work on carob generally rather than reporting new data, and it evaluates no branded carob extract.
- In vitro antioxidant and inhibitory activity of water decoctions of carob tree (Ceratonia siliqua L.) on cholinesterases, α-amylase and α-glucosidase. Nat Prod Res. 2015;29(22):2155-9. doi: 10.1080/14786419.2014.996147.PubMedUsed to support: Test-tube study of water decoctions prepared from carob leaf, germ flour, pulp, locust bean gum and stem bark, tested against α-amylase, α-glucosidase and two cholinesterases. The leaf and stem-bark decoctions inhibited all the enzymes most strongly and had the highest phenolic content, with gallic acid the major compound identified in the leaves and gentisic acid in the bark. No animals or people were involved, and the pod and seed material used in supplements was not the most active fraction.
- Carob pulp preparation rich in insoluble dietary fibre and polyphenols increases plasma glucose and serum insulin responses in combination with a glucose load in humans. Br J Nutr. 2007;98(1):101-5. doi: 10.1017/S0007114507701642.PubMedUsed to support: Randomized single-blind crossover study in 20 healthy adults aged 22-62 given a 50 g glucose drink with 0, 5, 10 or 20 g of polyphenol-rich carob pulp fiber. The 5 g and 10 g doses raised plasma glucose by 47% and 64% and serum insulin by 19.9% and 24.8% compared with the glucose drink alone; acylated ghrelin did not change significantly, and total ghrelin fell only after the 10 g dose. The authors concluded this suggests a deterioration in glycaemic control. The same German group published a companion carob-fiber study in 19 healthy volunteers, so these are related reports from one research programme rather than independent replications.
- Short-term effects of a low glycemic index carob-containing snack on energy intake, satiety, and glycemic response in normal-weight, healthy adults: Results from two randomized trials. Nutrition. 2017;42:12-19. doi: 10.1016/j.nut.2017.05.011.PubMedUsed to support: Two randomized crossover studies in healthy normal-weight adults: 10 for the glycaemic index measurement, 50 for the preload comparison. The carob snack was a low-glycaemic-index food (GI 40 versus 78 for a matched chocolate cookie); eaten before a meal it reduced hunger, desire to eat and preoccupation with food, and participants then ate less food and took in less total energy. The tested item was a carob-containing snack food, not a concentrated carob extract, and the effects were acute.
- Supplementation with a Carob (Ceratonia siliqua L.) Fruit Extract Attenuates the Cardiometabolic Alterations Associated with Metabolic Syndrome in Mice. Antioxidants (Basel). 2020;9(4):339. doi: 10.3390/antiox9040339.PubMedUsed to support: Animal study of CSAT+® at 4.8% of the diet in C57BL/6J mice fed a high-fat, high-sugar diet for 26 weeks. Csat+ lowered blood glucose, HOMA-IR, insulin, total and LDL cholesterol and IL-6, prevented diet-induced hypertension and improved endothelial function and cardiac recovery after ischaemia-reperfusion. Mouse evidence, funded by the company that sells the ingredient.
- Carob Extract Supplementation Together with Caloric Restriction and Aerobic Training Accelerates the Recovery of Cardiometabolic Health in Mice with Metabolic Syndrome. Antioxidants (Basel). 2022;11(9):1803. doi: 10.3390/antiox11091803.PubMedUsed to support: Animal study adding CSAT+® at 4.8% of the diet to two weeks of calorie reduction, with or without aerobic training, in mice with diet-induced metabolic syndrome. Only the Csat+ groups showed extra body-weight loss, reduced epididymal fat, higher adiponectin, lower IL-6 and improved insulin sensitivity in liver and skeletal muscle; Csat+ was also the only intervention that reduced obesity-related hypertension. Mouse evidence, carried out with and funded by the manufacturer.
- Effects of carob (Ceratonia siliqua) and carob-derived products on glycaemic control and insulin resistance: A systematic review of clinical trials. Nutr Res. 2026;152:81-98. doi: 10.1016/j.nutres.2026.05.007. PROSPERO CRD420251241518.PubMedUsed to support: Systematic review of 15 human clinical trials of carob and carob-derived products across healthy adults, prediabetes and type 2 diabetes. Carob-containing solid foods generally produced low-to-moderate post-meal glucose responses, whereas isolated carob powder or fiber given in liquid form produced weaker and more variable effects. The reviewers concluded that carob-specific insulin-sensitising effects remain preliminary and that longer, adequately powered trials with HbA1c endpoints are needed. This is a review, not a trial.
- Unveiling the microbiome-mediated potential of a carob-based formulation (Csat®): human fecal fermentation, SCFA production, and potential connections with satiety pathways. Food Bioscience. 2026;78:108472. doi: 10.1016/j.fbio.2026.108472.SourceUsed to support: Laboratory fermentation study in which Csat® was incubated with human faecal microbiota under anaerobic conditions and compared against a control medium and two isolated carob fractions (a galactomannan-rich seed fraction and a pulp extract), with microbial composition read by full-length 16S rRNA sequencing and short-chain fatty acids by GC-FID. Csat® shifted microbial composition and increased short-chain fatty acid production. This was an in vitro model: no person consumed the ingredient, and appetite and body weight were not assessed. Published in Food Bioscience 2026, DOI 10.1016/j.fbio.2026.108472; the journal is not indexed in MEDLINE, so the paper has no PMID.
- Evaluation of Commercial Carob Syrups (Ceratonia siliqua L.) in Randomized Controlled Trials: Effects on Lipid, Glycaemic, and Anthropometric Parameters. Foods. 2025;14(21):3676. doi: 10.3390/foods14213676.PubMedUsed to support: Two randomized controlled trials of commercial carob syrups in healthy adults aged 18 to 65. In a 20-person glycaemic test, the syrups had glycaemic indices of about 56 and 60 and blunted the glucose response by about 16% compared with glucose. In a 6-week trial in 72 adults taking 10 g of syrup on 6 days a week, total cholesterol fell 14.68 mg/dL within the carob group and 9.57 mg/dL in the control group, and waist circumference fell 3.58 cm within the carob group; the full text states that no lipid difference between groups was statistically significant, and the 0.49 kg weight change was not significant. A carob syrup food, not Csat+.
- Carob pulp preparation rich in insoluble fibre lowers total and LDL cholesterol in hypercholesterolemic patients. Eur J Nutr. 2003;42(5):235-42. doi: 10.1007/s00394-003-0438-y.PubMedUsed to support: Randomized, double-blind, placebo-controlled 6-week trial in 58 adults with high cholesterol eating bread and a fruit bar with or without 15 g a day of carob pulp fiber. LDL cholesterol fell 10.5% with carob fiber (p = 0.010); the LDL:HDL ratio fell 7.9% compared with placebo (p = 0.058), and triglycerides fell 11.3% in women. Carob pulp fiber in foods, not Csat+.
- Insoluble carob fiber rich in polyphenols lowers total and LDL cholesterol in hypercholesterolemic sujects. Plant Foods Hum Nutr. 2010;65(1):50-6. doi: 10.1007/s11130-009-0153-9.PubMedUsed to support: Randomized, double-blind, placebo-controlled 4-week trial in 88 adults with high cholesterol taking 4 g twice a day of an insoluble carob fiber rich in polyphenols. Compared with baseline, total cholesterol fell 17.8%, LDL 22.5% and triglycerides 16.3%, while the placebo group's lipids did not change significantly. A carob fiber preparation, not Csat+.
- Carob pulp preparation for treatment of hypercholesterolemia. Adv Ther. 2001;18(5):230-6. doi: 10.1007/BF02853169.PubMedUsed to support: Open-label, uncontrolled 8-week pilot in 47 adults with moderately high cholesterol eating 15 g a day of carob pulp preparation in foods: total and LDL cholesterol fell 7.8% and 12.2% at 6 weeks. Only 3 volunteers (6%) reported a feeling of fullness. No control group, and not Csat+.